FDA authorizes test to identify recent or prior COVID-19 infection
![fda-product-update](/sites/default/files/styles/900x400/public/2018-07/fda-product-update.jpg?itok=6i_6bhqt)
The Food and Drug Administration last week authorized for emergency use a test kit to help identify individuals with an adaptive immune response to SARS-CoV-2, indicating a recent or prior infection. Only laboratories certified under the Clinical Laboratory Improvement Amendments that meet requirements to perform high or moderate complexity tests may use the Diazyme SARS-CoV-2 Neutralizing Antibody CLIA Kit. Negative results do not preclude acute COVID-19 infection, the agency said.
Related News Articles
Headline
The Food and Drug Administration Aug. 22 granted emergency use authorization for two new combined COVID-19 and influenza tests. The Nano-Check Influenza-COVID-…
Headline
The Centers for Disease Control and Prevention's COVID-19 data tracker shows an 18.1% test positivity rate for the week ending Aug. 10, the highest it has been…
Headline
The Centers for Disease Control and Prevention Aug. 13 issued an advisory alerting of an uptick of cases of parvovirus B19 across the U.S. Parvovirus B19 is a…
Blog
The RAND Corporation recently released the fifth iteration of its biannual hospital price report. The AHA has previously highlighted significant flaws with…
Headline
Adults age 65 and older are encouraged to receive an updated dosage of the COVID-19 vaccine, the Centers for Disease Control and Prevention announced April 25…
Headline
The Pfizer and Moderna COVID-19 vaccines can cause myocarditis, but do not appear to cause infertility, Guillain-Barré syndrome, Bell’s palsy, thrombosis with…